MetaVia Inc. (MTVA)
MTVA Stock Price Chart
Explore MetaVia Inc. interactive price chart. Choose custom timeframes to analyze MTVA price movements and trends.
MTVA Company Profile
Discover essential business fundamentals and corporate details for MetaVia Inc. (MTVA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Aug 2016
Employees
9.00
Website
https://www.metaviatx.comCEO
Hyung Heon Kim
Description
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
MTVA Financial Timeline
Browse a chronological timeline of MetaVia Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.85.
Earnings released on 14 May 2026
EPS came in at -$0.79 falling short of the estimated -$0.76 by -3.95%.
Earnings released on 26 Mar 2026
EPS came in at $1.01 surpassing the estimated -$2.06 by +149.03%.
Stock split effective on 5 Dec 2025
Shares were split 1 : 11 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 6 Nov 2025
EPS came in at -$1.54 surpassing the estimated -$2.86 by +46.15%.
Earnings released on 7 Aug 2025
EPS came in at -$0.26 surpassing the estimated -$0.32 by +18.75%.
Earnings released on 14 May 2025
EPS came in at -$0.36 surpassing the estimated -$0.57 by +36.84%.
Earnings released on 31 Dec 2024
EPS came in at -$6.59 .
Earnings released on 7 Nov 2024
EPS came in at -$0.55 surpassing the estimated -$0.73 by +24.66%.
Earnings released on 14 Aug 2024
EPS came in at -$1.85 falling short of the estimated -$1.38 by -34.06%.
Earnings released on 31 Mar 2024
EPS came in at -$14.51 falling short of the estimated -$1.10 by -1.22k%.
Earnings released on 31 Dec 2023
EPS came in at -$11.51 .
Stock split effective on 21 Dec 2023
Shares were split 1 : 8 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Sept 2023
EPS came in at -$8.27 falling short of the estimated -$0.88 by -840.24%.
Earnings released on 30 Jun 2023
EPS came in at -$1.60 falling short of the estimated -$1.04 by -53.46%.
Earnings released on 31 Mar 2023
EPS came in at -$5.66 falling short of the estimated -$0.48 by -1.08k%.
Earnings released on 31 Dec 2022
EPS came in at -$19.12 .
Earnings released on 30 Sept 2022
EPS came in at -$308.25 .
Stock split effective on 13 Sept 2022
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Jun 2022
EPS came in at -$327.06 .
Earnings released on 31 Mar 2022
EPS came in at -$284.68 .
Earnings released on 31 Dec 2021
EPS came in at -$485.32 .
Earnings released on 30 Sept 2021
EPS came in at -$410.02 .
MTVA Stock Performance
Access detailed MTVA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
